Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
53 hedge funds and large institutions have $3.1M invested in Infinity Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 18 closing their positions.
175% more call options, than puts
Call options by funds: $22K | Put options by funds: $8K
6.41% less ownership
Funds ownership: 28.05% → 21.64% (-6.4%)
22% less funds holding
Funds holding: 68 → 53 (-15)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
78% less capital invested
Capital invested by funds: $13.9M → $3.1M (-$10.8M)
83% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$444K |
| 2 |
E
Ergoteles
New York
|
+$278K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$175K |
| 4 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$76.4K |
| 5 |
VF
Virtu Financial
New York
|
+$48.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$1.15M |
| 2 |
GC
Gratus Capital
Atlanta,
Georgia
|
-$735K |
| 3 |
Mariner
Overland Park,
Kansas
|
-$672K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$586K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$303K |
INFI Hedge Fund Activity: Q1 2023 in Review
53 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2023, worth a combined $3.1M — down 78% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of INFI and 3 opened new positions — a net loss of 15 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Carlson Capital, opening a new position worth an estimated $444K. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $1.15M sold.
- 53 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2023, down from 68 in Q4 2022.
- Funds reported $3.1M of Infinity Pharmaceuticals, Inc. stock for Q1 2023, down 78% quarter-over-quarter.
- 3 funds opened new Infinity Pharmaceuticals, Inc. positions in Q1 2023 and 18 closed out, a net change of -15 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q1 2023 was Carlson Capital, an estimated $444K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2023 was Polar Capital Holdings, an estimated $1.15M sold.
Based on aggregated 13F filings for Q1 2023.